LBPH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LBPH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Longboard Pharmaceuticals's Tax Expense for the three months ended in Mar. 2024 was $0.00 Mil. Longboard Pharmaceuticals's Pre-Tax Income for the three months ended in Mar. 2024 was $-14.99 Mil. Therefore, Longboard Pharmaceuticals's Tax Rate % for the quarter that ended in Mar. 2024 was 0.00%.
The historical data trend for Longboard Pharmaceuticals's Tax Rate % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Longboard Pharmaceuticals Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Tax Rate % | - | - | - | - |
Longboard Pharmaceuticals Quarterly Data | |||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Tax Rate % | Get a 7-Day Free Trial | - | - | - | - | - |
Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.
Longboard Pharmaceuticals's Tax Rate % for the fiscal year that ended in Dec. 2023 is calculated as
Tax Rate % | = | Tax Expense (A: Dec. 2023 ) | / | Pre-Tax Income (A: Dec. 2023 ) |
= | 0 | / | -54.422 | |
= | 0.00 % |
Longboard Pharmaceuticals's Tax Rate % for the quarter that ended in Mar. 2024 is calculated as
Tax Rate % | = | Tax Expense (Q: Mar. 2024 ) | / | Pre-Tax Income (Q: Mar. 2024 ) |
= | 0 | / | -14.986 | |
= | 0.00 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Longboard Pharmaceuticals's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.
Randall Kaye | officer: CMO | 11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121 |
Jane Tiller | director | C/O LONGBOARD PHARMACEUTICALS, INC., 4275 EXECUTIVE DRIVE, SUITE 950, LA JOLLA CA 92037 |
Brandi Roberts | officer: Chief Financial Officer | 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130 |
Phillip M Schneider | director | GEN-PROBE INCORPORATED, 10210 GENETIC CENTER DRIVE, SAN DIEGO CA 92121 |
Vincent Aurentz | director | C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Kevin Robert Lind | director, officer: President and CEO | C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Paul J Sekhri | director | C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588 |
Casey Lynch | director | C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Le Goff Corinne | director | 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139 |
Arena Pharmaceuticals Inc | 10 percent owner | 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Philip Perera | officer: Chief Medical Officer | C/O LONGBOARD PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
From GuruFocus
By PurpleRose PurpleRose • 08-03-2022
By GuruFocus Research • 11-02-2023
By Business Wire • 08-03-2023
By Business Wire • 11-29-2023
By Business Wire • 11-21-2023
By Business Wire • 08-03-2023
By Business Wire • 08-30-2023
By Business Wire Business Wire • 05-09-2023
By Business Wire Business Wire • 11-08-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.